title: Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift?
authors.affiliation: Profil Institute for Clinical Research, 855 3rd Ave, Suite 4400, Chula Vista, CA, 91911, USA, andrew.krentz@profilinstitute.com.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Krentz
authors.forename: Marcus
authors.initials: M
authors.lastname: Hompesch
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D050260:Carbohydrate Metabolism; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007333:Insulin Resistance; D050356:Lipid Metabolism; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D019440:Anti-Obesity Agents; D004338:Drug Combinations; D007004:Hypoglycemic Agents